Need To Know
- The $70 million Illinois verdict is one of several major outcomes in the NEC baby formula litigation
- NEC is a serious intestinal condition that primarily affects premature babies
- Lawsuits claim manufacturers failed to warn about the potential risks of cow’s milk-based formula
- NEC preterm infant formula lawsuits are being filed in state and federal courts
An Illinois jury has awarded $70 million to four families who alleged that their premature infants developed necrotizing enterocolitis (NEC) after being fed formula in the hospital, marking another significant development in ongoing litigation over preterm infant nutrition products.
The Cook County verdict includes $53 million in compensatory damages for harm suffered and $17 million in punitive damages, intended to punish the conduct and deter similar actions in the future. Together, the award reflects both the severity of the injuries involved and the arguments presented at trial.
The case involved infants who were fed Similac Special Care 24, a cow’s milk-based formula manufactured by Abbott Laboratories, while in neonatal intensive care units. Each later developed NEC, a serious and potentially life-threatening intestinal condition that primarily affects premature babies.
Although all four children survived, evidence presented at trial showed lasting complications, including multiple surgeries, extended hospitalizations, and long-term health challenges.
Latest in a Series of NEC Verdicts
The Illinois verdict is the latest in a growing number of NEC formula cases to reach juries in state courts and one of several to result in substantial damages awards.
In recent years, similar NEC lawsuits have produced substantial awards, including a $60 million verdict against Mead Johnson and another case involving hundreds of millions of dollars in combined compensatory and punitive damages against Abbott Laboratories.
Some defense verdicts have been returned, underscoring the complexity of the scientific and medical issues at the center of these cases, particularly questions about causation and whether cow’s milk-based formula increases the risk of NEC compared to breast milk.
While state court cases continue to move forward, the federal litigation remains in a different position.
NEC preterm infant formula claims have been consolidated into multidistrict litigation (MDL) in the Northern District of Illinois, where bellwether trials are intended to help test key issues before a broader group of cases proceeds.
Some early federal bellwether cases have been narrowed or dismissed on evidentiary and causation grounds. Another case, Inman v. Mead Johnson & Company, LLC, et al., is currently scheduled for later in 2026.
No NEC baby formula case in the federal MDL has yet been decided by a jury or resolved through settlement or jury trial, leaving many of the central legal and scientific questions unresolved at the federal level.
What This Verdict May Indicate Going Forward
With federal trials still pending, state court outcomes like this one are drawing increased attention.
These cases may offer early insight into how juries evaluate the evidence, particularly in claims involving failure to warn and the alleged risks associated with certain cow’s milk-based preterm formulas.
As additional trials move forward, both in state courts and eventually in the MDL, these early verdicts could help shape the direction of the broader litigation.
For Families Seeking More Information
For many parents, the connection between NEC and formula feeding is not always clear at the time of treatment, and questions often arise later.
Families whose children were diagnosed with NEC after being fed preterm infant formula may wish to explore whether further investigation is appropriate. Reviewing medical records and understanding feeding histories can be an important first step.
Childers, Schlueter & Smith represents families nationwide in NEC baby formula litigation and offers free, no-obligation consultations. Those seeking more information can contact the firm online, use the live chat feature, or call 1-800-641-0098.
